suramin has been researched along with Carcinoma, Non-Small Cell Lung in 9 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Suramin inhibits the growth of non-small cell lung cancer (NSCLC) and breast cancer in vitro by blocking the action of most known growth factors." | 9.08 | Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies. ( Bergh, J; Jakobsen, E; Lindebjerg-Clasen, B; Mirza, MR; Pfeiffer, P; Rose, C, 1997) |
| "Suramin inhibits the growth of non-small cell lung cancer (NSCLC) and breast cancer in vitro by blocking the action of most known growth factors." | 5.08 | Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies. ( Bergh, J; Jakobsen, E; Lindebjerg-Clasen, B; Mirza, MR; Pfeiffer, P; Rose, C, 1997) |
| " Target plasma concentrations were correctly predicted by our previously described dosing nomogram." | 2.75 | Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. ( Au, JL; Bekaii-Saab, T; Chen, L; Grever, M; Guillaume Wientjes, M; Jensen, RR; Lam, ET; Li, X; Murgo, AJ; Otterson, GA; Shen, T; Villalona-Calero, MA; Wei, Y, 2010) |
| " A dosing nomogram was developed by using population-based pharmacokinetic analysis of phase I results (15 patients, 85 treatment cycles), and evaluated in phase II patients (19 females, 28 males, 196 treatment cycles)." | 1.33 | Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development. ( Au, JL; Chen, D; Grever, M; Jensen, R; Murgo, AJ; Otterson, GA; Song, SH; Villalona-Calero, M; Wientjes, MG; Yeh, TK; Zhao, L, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Villalona-Calero, MA | 3 |
| Otterson, GA | 4 |
| Wientjes, MG | 3 |
| Weber, F | 1 |
| Bekaii-Saab, T | 2 |
| Young, D | 2 |
| Murgo, AJ | 4 |
| Jensen, R | 2 |
| Yeh, TK | 3 |
| Wei, Y | 2 |
| Zhang, Y | 1 |
| Eng, C | 1 |
| Grever, M | 4 |
| Au, JL | 5 |
| Lam, ET | 1 |
| Guillaume Wientjes, M | 1 |
| Chen, L | 1 |
| Shen, T | 1 |
| Li, X | 1 |
| Jensen, RR | 1 |
| Kanter, S | 1 |
| Fischer, B | 1 |
| DeHoff, C | 1 |
| Chen, D | 2 |
| Song, S | 1 |
| Lu, Z | 1 |
| Wientjes, TS | 1 |
| Song, SH | 1 |
| Zhao, L | 1 |
| Villalona-Calero, M | 1 |
| Favoni, RE | 1 |
| Ravera, F | 1 |
| Pirani, P | 1 |
| Ardizzoni, A | 1 |
| Noonan, D | 1 |
| de Cupis, A | 1 |
| Mirza, MR | 1 |
| Jakobsen, E | 1 |
| Pfeiffer, P | 1 |
| Lindebjerg-Clasen, B | 1 |
| Bergh, J | 1 |
| Rose, C | 1 |
| Lokshin, A | 1 |
| Peng, X | 1 |
| Campbell, PG | 1 |
| Barsouk, A | 1 |
| Levitt, ML | 1 |
| Putnam, EA | 1 |
| Yen, N | 1 |
| Gallick, GE | 1 |
| Steck, PA | 1 |
| Fang, K | 1 |
| Akpakip, B | 1 |
| Gazdar, AF | 1 |
| Roth, JA | 1 |
4 trials available for suramin and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 2008 |
Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, | 2010 |
Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; D | 2003 |
Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans | 1997 |
5 other studies available for suramin and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bromodeo | 2005 |
Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development.
Topics: Algorithms; Antineoplastic Agents; Blood Proteins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clin | 2006 |
Suramin interferes with auto/paracrine insulin-like growth factor I-controlled proliferative loop on human lung cancer cell lines.
Topics: Adenocarcinoma; Binding, Competitive; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell | 1994 |
Mechanisms of growth stimulation by suramin in non-small-cell lung cancer cell lines.
Topics: Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Cell Division; Dime | 1999 |
Autocrine growth stimulation by transforming growth factor-alpha in human non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Humans; L | 1992 |